PPIA and acute respiratory distress syndrome: These findings suggested that targeting a PARP3/Ppia/NF-κB signaling circuit with PARP3 inhibitor, alone or with NF-κB antagonists, might be a potential therapeutic for PARP3-overexpressing in ALI.